Translational Research

  • Success Stories

    Success Stories

    We have a strong culture of translating research outcomes including our RPOC CD4 Test.

A major strategic focus is the translation of our research into tangible benefits for the global community

Initiatives that nurture Burnet’s innovation and excellence are supported, with an emphasis on activities that draw on expertise from across the Institute.

We work in collaboration with commercial partners to develop its intellectual property (IP) and over many years have developed a number of applications that are now in use around the world.

There is a focus on bringing investment into the Institute that supports and furthers priority research agendas, and fostering collaboration both within the Institute and with external partners.

For scientists, this might mean support in sourcing investment in (and protecting) their IP that allows their work to progress to the next level; for public health researchers, the support offered by the team might result in diversified funding sources and/or international collaborators that extend the reach of their projects/studies.


Take a look at the range of opportunities to partner with us in translating research into tangible commercial outcomes.


The team is a key link in supporting the advancement of priority research agendas and fostering collaboration both within the Institute and with external partners.


Burnet has developed relationships with a number of commercial partners for the further development of its IP including:

  • Select Vaccines Ltd
  • Prima BioMed Ltd
  • SciVentures Ltd
  • IgaVax Pty Ltd
  • 4G Vaccines Pty Ltd
  • SeeD4 Pty Ltd

More information about these relationships is available on the Partnerships section of this site.

Contact Details

Geoff Drenkhahn

Director, Strategic Funding & Partnerships